What is B. Riley’s Forecast for Electromed Q3 Earnings?

Electromed, Inc. (NYSE:ELMD) – Investment analysts at B. Riley issued their Q3 2025 EPS estimates for Electromed in a report issued on Wednesday, February 19th. B. Riley analyst K. Bauser forecasts that the company will post earnings per share of $0.19 for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. B. Riley also issued estimates for Electromed’s Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.20 EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.31 EPS, FY2026 earnings at $1.00 EPS and FY2027 earnings at $1.16 EPS.

Separately, StockNews.com downgraded Electromed from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Electromed Stock Down 3.6 %

ELMD opened at $26.97 on Monday. The stock’s fifty day moving average is $31.37 and its two-hundred day moving average is $25.49. The company has a market capitalization of $230.78 million, a P/E ratio of 35.96 and a beta of 0.33. Electromed has a 52 week low of $13.74 and a 52 week high of $35.56.

Insider Buying and Selling at Electromed

In other news, Director Andrew Summers sold 17,463 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $30.09, for a total value of $525,461.67. Following the completion of the transaction, the director now directly owns 189,838 shares of the company’s stock, valued at approximately $5,712,225.42. The trade was a 8.42 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kathleen Skarvan sold 8,640 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $32.25, for a total value of $278,640.00. Following the sale, the director now owns 71,576 shares of the company’s stock, valued at $2,308,326. This trade represents a 10.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 163,812 shares of company stock valued at $4,728,773. Company insiders own 14.00% of the company’s stock.

Hedge Funds Weigh In On Electromed

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ritholtz Wealth Management bought a new stake in shares of Electromed in the 4th quarter valued at about $488,000. Barclays PLC purchased a new stake in Electromed during the third quarter valued at approximately $215,000. Navellier & Associates Inc. acquired a new stake in Electromed in the third quarter valued at approximately $368,000. State Street Corp grew its holdings in Electromed by 14.5% in the third quarter. State Street Corp now owns 22,066 shares of the company’s stock worth $474,000 after purchasing an additional 2,800 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of Electromed during the third quarter worth $274,000. Hedge funds and other institutional investors own 40.82% of the company’s stock.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.